David Song

Dr. David Song

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Medicine
Verified
Journal Article
Open access
AJAkash Jaiswal
Akash Jaiswal
VJVikash Jaiswal
Vikash Jaiswal
SASong Peng Ang
Song Peng Ang
MHMUHAMMAD HANIf
MUHAMMAD HANIf
AVAnanya Mbbs Vadhera
Ananya Mbbs Vadhera
MBMonodeep Biswas
Monodeep Biswas
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been recommended in the practice guidelines for the treatment of patients with heart failure with reduced ejection fraction; however, their effects among patients with preserved ejection fraction have been debatable. Objective: We aim to evaluate the SGLT2 inhibitor effect among patients with heart failure with reduced ejection fraction, including DELIVER and EMPEROR-Preserved trials. Methods: We performed a systematic literature search using the PubMed, Embase, Scopus, and Cochrane libraries for relevant articles from inception until August 30th, 2022. Statistical analysis was performed by calculating hazard ratio (HR) using the random effect model with a 95% confidence interval (CI) and probability value (P). Statistical significance was met if 95% CI does not cross numeric “1” and P < .05. Results: Six studies with a total of 15,989 total patients were included in the final analysis. The mean age of patients enrolled in SGLT2 inhibitors and placebo was 69.13 and 69.37 years, respectively. The median follow-up duration was 2.24 years. SGLT2 inhibitors reduced composite cardiovascular mortality or first hospitalization for heart failure (HR, 0.80 [95% CI: 0.74–0.87], P < .001, I 2 = 0%), heart failure hospitalization (HR, 0.74 [95% CI: 0.67–0.82], P < .001, I 2 = 0%) compared with placebo. However, all-cause mortality (HR, 0.97 [95% CI: 0.89–1.06], P = .54, I 2 = 0%) and cardiovascular mortality (HR, 0.96 [95% CI: 0.82–1.13), P = .66, I 2 = 35.09%] were comparable between both groups. Conclusion: Our study finding shows that SGLT2 inhibitors significantly reduced the risk of first HF hospitalization or cardiovascular death and HF hospitalization; however, all-cause mortality was comparable between the groups.

2 March 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
YSyasar sattar
yasar sattar
UTUsama Talib
Usama Talib
MFMohammed Faisaluddin
Mohammed Faisaluddin
DSDavid Song
David Song
HLHassan Mehmood Lak
Hassan Mehmood Lak
MAMahboob Alam
Mahboob Alam

30 June 2023 in Medicine
Verified
Journal Article
Open access
VJVikash Jaiswal
Vikash Jaiswal
SASong Peng Ang
Song Peng Ang
ASAbhigan babu Shrestha
Abhigan babu Shrestha
ZWZarghoona Wajid
Zarghoona Wajid
EEEndurance Osas Evbayekha
Endurance Osas Evbayekha
MBMonodeep Biswas
Monodeep Biswas
Background: The Amplatzer Amulet (AA) and Watchman devices (WD) are the 2 most frequently used devices for percutaneous LAA closure globally. Objective: To evaluate the safety and clinical outcomes associated with these 2 devices in patients undergoing percutaneous LAA closure. Method: We systematically searched all electronic databases from inception until February 21, 2023. The primary endpoint was procedure related complications. Secondary endpoints were device related thrombus, stroke, cardiovascular mortality, peri device leak, systemic embolism, and all-cause mortality. Results: A total of 3 randomized clinical trials with 2150 patients were included in this meta-analysis. The mean age was 75 and 76 years in the Amplatzer group and in the Watchman group, respectively. The odds of procedure-related complications (OR, 1.80 [95% CI: 1.21–2.67], P < .001) were significantly higher among patients with AA compared to the WD. However, the odds of all-cause mortality (OR, 0.75 (95% CI: 0.49–1.16), P = .20), stroke (OR, 0.79 [95% CI: 0.47–1.34], P = .39), systemic/pulmonary embolism (OR, 1.34 [95% CI: 0.30–6.04], P = .70), and major bleeding (OR, 1.10 [95% CI: 0.83–1.48], P = .50) were comparable between the two devices. The odds of device related thrombus (OR, 0.72 [95% CI: 0.46–1.14], P = .17) was comparable between both the group of patients, however the incidence of peri device leak was significantly lower in AA group (OR, 0.41 [95% CI: 0.26–0.66], P < .001) compared with WD group of patients. Conclusion: The AA was not superior to the Watchman device in terms of safety and efficacy. However, the Amulet occluder was associated with a higher incidence of procedure-related complications, and lower peri device leak.

16 January 2023 in Clinical Case Reports
Verified
Journal Article
Open access
JRJonathan Vincent M. Reyes
Jonathan Vincent M. Reyes
MDManasa Dondapati
Manasa Dondapati
SASaad Ahmad
Saad Ahmad
DSDavid Song
David Song
JLJoseph J. Lieber
Joseph J. Lieber
VJVikash Jaiswal
Vikash Jaiswal
Streptococcus intermedius is a beta‐hemolytic, non‐motile, catalase‐negative, gram‐positive member of the Streptococcus anginosus group. When compared to other members of this group like S. anginosus and Streptococcus constellatus , S. intermedius infections are more substantial. In this case, we present a 47‐year‐old male patient who was found to have S. intermedius abscesses in his lungs, liver, and brain. The treatment of choice for these abscesses is a combination of drainage, surgery, and antibiotic therapy.

21 June 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MFMohammed Faisaluddin
Mohammed Faisaluddin
YSYasar Sattar
Yasar Sattar
DSDavid Song
David Song
ATAnoop Titus
Anoop Titus
SESaliha Erdem
Saliha Erdem
RDRamesh Daggubati
Ramesh Daggubati

1 January 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
YSYasar Sattar
Yasar Sattar
DSDavid Song
David Song
RKRitika Kompella
Ritika Kompella
JAJunaid Arshad
Junaid Arshad
MZMohamed Zghouzi
Mohamed Zghouzi
MAM. Chadi Alraies
M. Chadi Alraies